Observational studyIntensive care medicine2025
Management of high-risk acute pulmonary embolism: an emulated target trial analysis.
Observational study in Intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mechanical Thrombectomy Versus Systemic Thrombolysis in Hemodynamically Unstable High-Risk Pulmonary Embolism Requiring Vasopressors: A Propensity-Matched Outcomes Analysis From TriNetX Network.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Reperfusion Therapy and Outcomes in High-Risk Pulmonary Embolism: Multicenter Registry Study From the Tokyo Cardiovascular Care Unit Network.Circulation reports · 2026Article
- Heparin and Venoarterial Extracorporeal Membrane Oxygenation in Massive Pulmonary Embolism Management: A Case Report.The American journal of case reports · 2026Article
- ECMO-assisted catheter-directed thrombolysis for post-traumatic pulmonary embolism with bilateral atrial thrombi: a retrospective case series.Journal of cardiothoracic surgery · 2026Article
- Article
- Clinical Outcomes and Treatment Strategies in Catastrophic High-Risk Pulmonary Embolism: A Retrospective Analysis.Journal of cardiovascular development and disease · 2025Article
- Opportunities, challenges and future perspectives for target trial emulation in critical care clinical research.Critical care (London, England) · 2025Review
- Article
- The dawn of target trials in intensive care: time to move beyond association is not causation.Intensive care medicine · 2025Article
- Diagnostic Performance of Salusins in Acute Pulmonary Embolism: A Prospective Observational Study.Diagnostics (Basel, Switzerland) · 2025Article
- [Extracorporeal cardiopulmonary resuscitation in postpartum pulmonary embolism].Die Anaesthesiologie · 2025Article
- Prehospital thrombolytic treatment of high-risk acute pulmonary embolism.Critical care (London, England) · 2025Article
- Case Report of Successful Extracorporeal CPR (eCPR) in Refractory Cardiac Arrest Caused by Fulminant Pulmonary Embolism with Remarkable Recovery.Reports (MDPI) · 2025Article
- Personalized strategies for high-risk acute pulmonary embolism: addressing the "catastrophic" subgroup. Author's reply.Intensive care medicine · 2025Article
- Personalized strategies for high-risk acute pulmonary embolism: addressing the "catastrophic" subgroup.Intensive care medicine · 2025Article
- High-risk pulmonary embolism: the significance and perspectives of pulmonary reperfusion.Intensive care medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
68 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-risk acute pulmonary embolism (PE) is a life-threatening condition necessitating hemodynamic stabilization and rapid restoration of pulmonary perfusion. In this context, evidence regarding the benefit of advanced circulatory support and pulmonary recanalization strategies is still limited.
methodsIn this observational study, we assessed data of 1060 patients treated for high-risk acute PE with 991 being included in a target trial emulation to investigate all-cause in-hospital mortality estimates with different advanced treatment strategies. The four treatment groups consisted of patients undergoing (I) veno-arterial extracorporeal membrane oxygenation (VA-ECMO) alone (n = 126), (II) intrahospital systemic thrombolysis (SYS) (n = 643), (III) surgical thrombectomy (ST) (n = 49), and (IV) percutaneous catheter-directed treatment (PCDT) (n = 173). VA-ECMO was allowed as bridging to pulmonary recanalization in groups II, III, and IV. Marginal causal contrasts were estimated using the g-formula with logistic regression models as the primary approach. Sensitivity analyses included targeted maximum likelihood estimation (TMLE) with machine learning, inverse probability of treatment weighting (IPTW), as well as variations of estimands, handling of missing values, and a complete target trial emulation excluding the VA-ECMO alone group.
resultsIn the overall target trial population, the median age was 62.0 years, and 53.3% of patients were male. The estimated probability of in-hospital mortality from the primary target trial intention-to-treat analysis for VA-ECMO alone was 57% (95% confidence interval [CI] 47%; 67%), compared to 48% (95% CI 44%; 53%) for intrahospital SYS, 34% (95%CI 18%; 50%) for ST, and 43% (95% CI 35%; 51%) for PCDT. The mortality risk ratios were largely in favor of any advanced recanalization strategy over VA-ECMO alone. The robustness of these findings was supported by all sensitivity analyses. In the crude outcome analysis, patients surviving to discharge had a high probability of favorable neurologic outcome in all treatment groups.
conclusionAdvanced recanalization by means of SYS, ST, and several promising catheter-directed systems may have a positive impact on short-term survival of patients presenting with high-risk PE compared to the use of VA-ECMO alone as a bridge to recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.